News &amp; Updates

Regular statin users appear to be at lower risk of developing diabetes mellitus following an episode of acute pancreatitis, as shown in a study.

Regular statin use offers protection against diabetes in acute pancreatitis patients

Glargine, degludec improve glycaemic control in patients switching from first-gen insulin

Among type 2 diabetes (T2D) patients on first-generation basal insulins (1BIs), a switch to either glargine or degludec in the real-world setting leads to marked improvements in glucose control without increasing the risk of hypoglycaemic events and weight gain, according to a study. Furthermore, the benefits seem to be comparable between the two second-generation basal insulins (2BIs).

Glargine, degludec improve glycaemic control in patients switching from first-gen insulin

Revacept beneficial to patients with symptomatic ICA stenosis

Patients with symptomatic internal carotid artery (ICA) stenosis may fare well with revacept, a competitive antagonist of glycoprotein VI, as the drug helps reduce the incidence of stroke or death, transient ischaemic attack, and bleeding complications, among others, according to a study.

Revacept beneficial to patients with symptomatic ICA stenosis

$Add-on baclofen eases reflux in certain PPI-refractory GERD patients$

Add-on baclofen eases reflux in certain PPI-refractory GERD patients

In patients with proton pump inhibitor (PPI)-refractory gastroesophageal reflux disease (GERD), add-on treatment with baclofen improves several reflux parameters, but only among those who are positive for symptom association probability, a study has found.

Add-on baclofen eases reflux in certain PPI-refractory GERD patients

P-gp/CYP3A4 inhibitor use ups bleeding, mortality risks in NOAC-treated AF patients

Bleeding and mortality risks are elevated in atrial fibrillation (AF) patients treated with nonvitamin K antagonist oral anticoagulant (NOAC) who are also using P-glycoprotein (P-gp) and CYP3A4 inhibitors, reports a study, noting the need for close monitoring of these individuals.

P-gp/CYP3A4 inhibitor use ups bleeding, mortality risks in NOAC-treated AF patients

Novel oral neoadjuvant therapy shows promising phase II results

The novel neoadjuvant therapy S-1, an oral fluoropyrimidine agent containing tegafur, gimeracil, and oteracil potassium, yields promising survival outcomes in high-risk patients with resectable pancreatic ductal adenocarcinoma, a recent study has found.

Novel oral neoadjuvant therapy shows promising phase II results

Tirzepatide: A winning weight-loss therapy for nondiabetic, obese adults

25 Jun 2022 by

Non-diabetic overweight or obese adults experienced a greater reduction in weight and cardiometabolic measures with the addition of tirzepatide to their lifestyle interventions, findings of the SURMOUNT-1 trial showed.

Tirzepatide: A winning weight-loss therapy for nondiabetic, obese adults

25 Jun 2022

PPIs raise death risk in advanced NSCLC patients on antitumour therapy

Treatment with proton pump inhibitors (PPI) appears to increase the risk of mortality among patients with advanced nonsmall cell lung cancer (NSCLC) undergoing systemic antitumour therapy, reveals a recent study.

PPIs raise death risk in advanced NSCLC patients on antitumour therapy

25 Jun 2022

Tranexamic acid does not prevent haemorrhage-related events in Caesarean section

Among women with multiple pregnancies, prophylactic treatment with tranexamic acid does not appear to reduce the incidence of blood loss-related events following caesarean delivery, a study has shown.

Tranexamic acid does not prevent haemorrhage-related events in Caesarean section